Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 25Hodgkin Disease 20Lymphoma 9Skin Neoplasms 4Neoplasm Metastasis 4Sarcoma 3Leiomyosarcoma 3Neuroblastoma 2Neoplasms 2Uveal Melanoma 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Melanoma, Cutaneous Malignant 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Liposarcoma 1

Interventions

Dexamethasone 28Rituximab 16pomalidomide 13Gemcitabine 12Lenalidomide 11Cisplatin 11Bortezomib 11Paclitaxel 10Cyclophosphamide 8Carboplatin 8carfilzomib 7selinexor 5daratumumab 5Drug Therapy 5Doxorubicin 5Cytarabine 5ibrutinib 4Vincristine 4Temozolomide 4Prednisone 4Docetaxel 4Calcium Dobesilate 4Bevacizumab 4Aspirin 4tisagenlecleucel 3Cetuximab 3Bendamustine Hydrochloride 3venetoclax 2ofatumumab 2galiximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Recurrence × Dacarbazine × Clear all
NCT02288897 2022-01-19

PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Provectus Pharmaceuticals

Phase 3 Terminated
20 enrolled 13 charts
Dermatologic

Melanoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡